400-900-4166

Recombinant Human Uracil phosphoribosyltransferase homolog/UPRT,BR

Recombinant Human Uracil phosphoribosyltransferase homolog/UPRT

(订货以英文名为准)
产品编号:AC81433 品牌:Acmec

猜你喜欢

硼烷二甲硫醚, 2.0 M solution in THF, SafeSeal

CAS No:13292-87-0

组胺, 分析对照品,HPLC≥98%

CAS No:51-45-6

溴化锂, 99.5% metals basis

CAS No:7550-35-8

CAS No:115383-22-7

聚乙二醇300, average Mn 300

CAS No:25322-68-3

a-葡萄糖苷酶, ≥40units/mg protein 酵母

CAS No:9001-42-7

聚乙二醇200单甲醚, 平均分子量200

CAS No:9004-74-4

中文名称:
Recombinant Human Uracil phosphoribosyltransferase homolog/UPRT
英文名称:
Recombinant Human Uracil phosphoribosyltransferase homolog/UPRT
保存条件:
-70°C

产品属性 Product Attributes

基本信息

别名: Uracil phosphoribosyltransferase homolog;UPP;FUR1;UPRT
规格: 10ug ; 50ug ; 500ug ; 1mg
外观(性状): Supplied as a 0.2 μm filtered solution of 20mM TrisHCl,150mM NaCl pH 8.0.
纯度: ≥95% as determined by reducing SDS-PAGE.
储存条件: Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

产品信息

背景说明: UPRT is a cytoplasmic enzyme which belongs to the UPRTase family.UPRT is highly expressed in leukocytes,liver,spleen and thymus,with lower expression in brain,lung and skeletal muscle.UPRTcatalyzes the conversion of uracil and 5-phosphoribosyl-1-R-diphosphate to uridine monophosphate (UMP).This reaction is an important part of nucleotide metabolism,specifically the pyrimidine salvage pathway.UPRT is a potential target for rational design of drugs to treat parasitic infections and cancer
来源: E.coli

其它标识

内毒素: Less than 0.1 ng/ug(1 EU/ug)as determined by LAL test.

产品介绍 Product Introduction

暂无数据

注意事项 Considerations

1.本产品仅供科研使用。请勿用于医药、临床诊断或治疗,食品及化妆品等用途。请勿存放于普通住宅区。
2.为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。
3.实验结果可由多种因素影响,相关处理只限于产品本身,不涉及其他赔偿。
危化品级别:
关于的化合物详细属性等信息,点击“
技术资料
DATA SHEET
历史浏览记录
​Copyright ◎ 2018 ACMEC-E.COM-版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
上海吉至生化科技有限公司
沪公网安备31012002005909号   沪ICP备18007380号-1
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
危险品化学品经营许可证    营业执照(三证合一)